NeurAxis, Inc. reported a 22% increase in revenues to $811 thousand in the third quarter of 2025 compared to $667 thousand in the same period last year. Operating loss also rose by 27% due to increased sales efforts. The company’s cash balance was $4.4 million as of September 30, 2025, with an additional $2.8 million raised in October through equity offerings. NeurAxis achieved FDA clearances for pain treatment in adults and children, expanding its total addressable market to approximately 55 million covered lives. They also received a new CPT code for PENFS procedures effective January 1, 2026, and FDA clearance for an expanded IB-Stim label. The company’s CEO, Brian Carrico, expressed optimism for substantial revenue growth in 2026, with recent FDA clearances broadening market opportunities. Revenues in the third quarter of 2025 increased by 22% to $811 thousand, with unit deliveries up by approximately 38% year over year. However, gross margin declined to 83.3% due to higher discounting for patients in financial assistance programs. Operating expenses and losses increased in the third quarter of 2025 compared to the same period in 2024. Net loss attributable to shareholders was $2.1 million in the third quarter of 2025. NeurAxis improved its liquidity position by raising $2.8 million in October 2025 through equity offerings and warrant exercises. The company will hold a conference call on Tuesday, November 11, 2025, at 9:00am ET. Interested parties can access the call via a live webcast or by registering for the live conference call. A webcast replay will also be available on the company’s website. NeurAxis, Inc. is a medical technology company focused on neuromodulation therapies for chronic conditions in both children and adults. They are dedicated to advancing science and leveraging evidence-based medicine to drive the adoption of their IB-Stim™ therapy. Forward-looking statements in this press release caution about risks and uncertainties that may affect the company’s business, strategy, or financial performance. NeurAxis can be contacted via email for more information.
Read more at GlobeNewswire: NeurAxis Reports Strong Third Quarter 2025 Financial
